| Ureter Carcinoma studied in …STUDIED_INderived24 of 24show fewer |
|---|
| → studied in | NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 24 trials mapped (15 active) | — | — | Muscle Invasive Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04963153Phase 1 · active not recruiting Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940299Phase 2 · active not recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ONTOLOGY_EXACT · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05059444recruiting ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation · condition mapped ONTOLOGY_EXACT · 24 trials mapped (15 active) | — | — | Ureter Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03244384Phase 3 · active not recruiting Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03237780Phase 2 · active not recruiting Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00942331Phase 3 · completed Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (15 active) | — | — | Ureter Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05092958Phase 3 · active not recruiting Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04953104Phase 2 · active not recruiting ARID1A and/or KDM6A Mutation and CXCL13 Expression · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04637594Phase 3 · active not recruiting Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04848519Phase 2 · active not recruiting Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03582475Phase 1 · active not recruiting Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate · condition mapped ALIAS · 24 trials mapped (15 active) | — | — | Ureter Small Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02567409Phase 2 · completed Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03513952Phase 2 · completed Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03397394Phase 2 · terminated Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (15 active) | — | — | Ureter Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00749892Phase 2 · completed Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01993979Phase 3 · unknown A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) · condition mapped ALIAS · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03935347Phase 2 · withdrawn Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02178241Phase 2 · completed Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery · condition mapped CURATED_BROADER · 24 trials mapped (15 active) | — | — | Ureter Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01282463Phase 2 · completed Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma · condition mapped ALIAS · 24 trials mapped (15 active) | — | — | Ureter Carcinoma | 1 | Observed | clinicaltrials | graph → |